Indefinite Delivery Contract SPE2DR25D9129

Award Date 8/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The federal contract IDV award is for an Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $499,999,999, provides a vehicle for the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This...
The federal contract IDV award SPE2DR25D9966 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical...
The federal contract IDV award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, is for an Indefinite Delivery Contract (IDC) valued at up to $499,999,999 through November 2026. This single-award IDC enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical...
The federal contract IDV award SPE2DR25D9767 is a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, which is valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications,...
The federal contract IDV award SPE2DU25D9770 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical...
The federal contract IDV award SPE2DU25D9166 was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The single-award $499,999,999 Indefinite Delivery Contract (IDC) enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical...
The federal contract IDV award is a single-award Indefinite Delivery Contract (IDC) between the Defense Logistics Agency (DLA) and DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. This includes branded and generic prescription...
The federal contract IDV award SPE2DR25D9124 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. The contract covers an extensive...
The federal contract IDV award is for an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) under the SPE2DB program. The prime contractor is DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The contract, valued at $499,999,999, enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications,...
The federal contract IDV award is for an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain, valued at up to $499,999,999 and valid through November 2026. The prime contractor is DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The IDC enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription...

The federal contract IDV award SPE2DR25D9129 is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The IDC, valued at $499,999,999 and valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support the medical supply needs of military health facilities worldwide.

The contracted products include branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various categories such as injections, tablets, creams, auto-injectors, and specialty medications. This IDC is part of the DLA Troop Support Medical Supply Chain's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which aims to establish multiple regional prime vendor contracts to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency (DHA), United States Coast Guard, and US Naval Fleet. The contracts will have a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion.

Generated 6/6/25, 9:53 AM